Author's response to reviews

**Title:** TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells

**Authors:**

Siyang Zhang (zhangsiyang_cmu11032@126.com)
Dawei Guo (gdw80@163.com)
Wenting Luo (lvirginia@163.com)
Qingfu Zhang (qingfu1981@126.com)
Ying Zhang (ZY20769876@yahoo.cn)
Chunyan Li (lichunyan915@yahoo.com.cn)
Yao Lu (luyao@mail.cmu.edu.cn)
Zeshi Cui (labczs@mail.cmu.edu.cn)
Xueshan Qiu (qiuxueshan_pathology@126.com)

**Version:** 3 **Date:** 27 January 2010

**Author's response to reviews:** see over
Dear Editor Tim,

Thank you for your letter. We are very pleased to learn that our manuscript is acceptable for publication in BMC Cancer.

We have completed the revised manuscript according to the queries mentioned in your letter, and checked the paper carefully. In the revised “NSCLC samples” section, “A total of 60 cases of NSCLC were obtained from the Pathology Department of China Medical University. This study was approved by the Medical Research Ethics Committee of China Medical University and the informed consent was obtained from all patients” is supplemented, which is highlighted in red in the revised paper. We hope that the revised manuscript is now acceptable.

We greatly appreciate your help concerning improvement to this manuscript. Also, we’ll keep the manuscript being revised until you’re satisfied with it. Thank you very much! If there are any more problems, please contact me without hesitation.

Best regards,

Xueshan Qiu